264 related articles for article (PubMed ID: 21990041)
1. The clinical implications and biologic relevance of neurofilament expression in gastroenteropancreatic neuroendocrine neoplasms.
Schimmack S; Lawrence B; Svejda B; Alaimo D; Schmitz-Winnenthal H; Fischer L; Büchler MW; Kidd M; Modlin I
Cancer; 2012 May; 118(10):2763-75. PubMed ID: 21990041
[TBL] [Abstract][Full Text] [Related]
2. Loss of expression and prognosis value of alpha-internexin in gastroenteropancreatic neuroendocrine neoplasm.
Wang Y; Chen Y; Li X; Hu W; Zhang Y; Chen L; Chen M; Chen J
BMC Cancer; 2018 Jun; 18(1):691. PubMed ID: 29940892
[TBL] [Abstract][Full Text] [Related]
3. GNA15 expression in small intestinal neuroendocrine neoplasia: functional and signalling pathway analyses.
Zanini S; Giovinazzo F; Alaimo D; Lawrence B; Pfragner R; Bassi C; Modlin I; Kidd M
Cell Signal; 2015 May; 27(5):899-907. PubMed ID: 25701539
[TBL] [Abstract][Full Text] [Related]
4. Clinico-morphological analysis of the neuroendocrine neoplasms of the gastroenteropancreatic system.
Delektorskaya VV; Kozlov NA; Chemeris GY
Klin Lab Diagn; 2013 Oct; (10):48-50, 10-3. PubMed ID: 24640093
[TBL] [Abstract][Full Text] [Related]
5. Chromogranin A in diagnosing and monitoring patients with gastroenteropancreatic neuroendocrine neoplasms: a large series from a single institution.
Massironi S; Rossi RE; Casazza G; Conte D; Ciafardini C; Galeazzi M; Peracchi M
Neuroendocrinology; 2014; 100(2-3):240-9. PubMed ID: 25428270
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical Study of Mitosis-regulatory Proteins in Gastroenteropancreatic Neuroendocrine Neoplasms.
Briest F; Wang Y; Arsenic R; Elezkurtaj S; Berg E; Greshake S; Lock AC; Hörsch D; Arnold CN; Hummel M; Siegmund B; Grabowski P
Anticancer Res; 2018 Jul; 38(7):3863-3870. PubMed ID: 29970506
[TBL] [Abstract][Full Text] [Related]
7. Chromogranin A and its fragments as regulators of small intestinal neuroendocrine neoplasm proliferation.
Giovinazzo F; Schimmack S; Svejda B; Alaimo D; Pfragner R; Modlin I; Kidd M
PLoS One; 2013; 8(11):e81111. PubMed ID: 24260544
[TBL] [Abstract][Full Text] [Related]
8. Role of PD-L1 expression as a biomarker for GEP neuroendocrine neoplasm grading.
Cavalcanti E; Armentano R; Valentini AM; Chieppa M; Caruso ML
Cell Death Dis; 2017 Aug; 8(8):e3004. PubMed ID: 28837143
[TBL] [Abstract][Full Text] [Related]
9. [Advances of circulating biomarkers in gastroenteropancreatic neuroendocrine neoplasms].
Chen L; Chen M; Chen J
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Mar; 20(3):357-360. PubMed ID: 28338171
[TBL] [Abstract][Full Text] [Related]
10. Reassessment of somatostatin receptor SST4 expression in bronchopulmonary and gastroenteropancreatic neuroendocrine neoplasms using the novel rabbit monoclonal anti-human SST4 antibody 7H49L61.
Ehms B; Kaemmerer D; Sänger J; Schulz S; Lupp A
Sci Rep; 2022 Aug; 12(1):14722. PubMed ID: 36042228
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study.
Zhang M; Zhao P; Shi X; Zhao A; Zhang L; Zhou L
BMC Endocr Disord; 2017 Jul; 17(1):39. PubMed ID: 28705205
[TBL] [Abstract][Full Text] [Related]
12. Single institutional experience on primary neuroendocrine neoplasms of the kidney: a rare distinct entity.
Amin M; Trikalinos N; Chatterjee D
Hum Pathol; 2021 Aug; 114():36-43. PubMed ID: 33891968
[TBL] [Abstract][Full Text] [Related]
13. Gastroenteropancreatic neuroendocrine neoplasms: a 10-year experience of a single center.
Lewkowicz E; Trofimiuk-Müldner M; Wysocka K; Pach D; Kiełtyka A; Stefańska A; Sowa-Staszczak A; Tomaszewska R; Hubalewska-Dydejczyk A
Pol Arch Med Wewn; 2015; 125(5):337-46. PubMed ID: 25924181
[TBL] [Abstract][Full Text] [Related]
14. The Correlation Between [
Yu J; Li N; Li J; Lu M; Leal JP; Tan H; Su H; Fan Y; Zhang Y; Zhao W; Zhu H; Pomper MG; Zhou Y; Yang Z
Mol Imaging Biol; 2019 Oct; 21(5):984-990. PubMed ID: 30796708
[TBL] [Abstract][Full Text] [Related]
15. The identification of gut neuroendocrine tumor disease by multiple synchronous transcript analysis in blood.
Modlin IM; Drozdov I; Kidd M
PLoS One; 2013; 8(5):e63364. PubMed ID: 23691035
[TBL] [Abstract][Full Text] [Related]
16. Models of Gastroenteropancreatic Neuroendocrine Neoplasms: Current Status and Future Directions.
Detjen K; Hammerich L; Özdirik B; Demir M; Wiedenmann B; Tacke F; Jann H; Roderburg C
Neuroendocrinology; 2021; 111(3):217-236. PubMed ID: 32615560
[TBL] [Abstract][Full Text] [Related]
17. Biomarkers in gastroenteropancreatic neuroendocrine neoplasms.
Jacoba IM; Weber HC
Curr Opin Endocrinol Diabetes Obes; 2023 Jun; 30(3):175-180. PubMed ID: 36895178
[TBL] [Abstract][Full Text] [Related]
18. Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms.
Janson ET; Sorbye H; Welin S; Federspiel B; Grønbæk H; Hellman P; Ladekarl M; Langer SW; Mortensen J; Schalin-Jäntti C; Sundin A; Sundlöv A; Thiis-Evensen E; Knigge U
Acta Oncol; 2014 Oct; 53(10):1284-97. PubMed ID: 25140861
[TBL] [Abstract][Full Text] [Related]
19. Variability of the Ki-67 proliferation index in gastroenteropancreatic neuroendocrine neoplasms - a single-center retrospective study.
Shi H; Zhang Q; Han C; Zhen D; Lin R
BMC Endocr Disord; 2018 Jul; 18(1):51. PubMed ID: 30055596
[TBL] [Abstract][Full Text] [Related]
20. Nuclear survivin is a prognosticator in gastroenteropancreatic neuroendocrine neoplasms: a meta-analysis.
Krieg S; Roderburg C; Fung S; Luedde T; Knoefel WT; Krieg A
J Cancer Res Clin Oncol; 2022 Sep; 148(9):2235-2246. PubMed ID: 35428913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
